Abstract:
Lower extremity arterial disease (LEAD) is not a curable disease and revascularization procedures have little or no effect on the overall life expectancy. Hence, treatment should be aimed primarily at alleviating symptoms, controlling risk factors and improving health-related quality of life (HRQOL). LEAD is associated with impaired HRQOL not only in physical domains but also in social function, emotional and mental health. LEAD is commonly associated with many risk factors each being capable to deteriorate HRQOL independently.
In contrast to the well-developed body of publications on surgical outcomes, prospective data on patient-oriented outcomes after revascularization are still lacking with a total volume of publications currently below 40.
The available data provide some evidence that successful revascularization immediately improves the HRQOL in patients suffering from ischemic claudication with a lasting benefit on physical functioning for at least 12 months while a trend toward return to baseline values in mental health, emotional and vitality domains is commonly observed. Surprisingly, patients with unsuccessful revascularization with minimal increase in lower limb blood flow still experience some improvement in pain, emotional reactions and family relationships in the first year. In the most severe form of LEAD (critical limb ischemia), an immediate and lasting benefit on HRQOL is seen after successful revascularization although less pronounced than in claudicants. However, despite long-term limb salvage and optimal graft functioning, patients successfully revascularized remain functionally disabled when compared to age-matched subjects, nevertheless they report similar well-being. After major limb amputation, some improvement in HRQOL can be expected through pain relief and the maintenance of mobility either with prosthetic rehabilitation or wheel chair ambulation.
The measurement of HRQOL is clearly needed at baseline and after vascular operations but its future role in the decision making process is yet to be defined.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ABI:
- CLI:
-
critical limb ischemia
- ET:
- HRQOL:
-
health-related quality of life
- IC:
-
intermittent claudication
- LEAD:
-
lower extremity arterial disease
- OVS:
-
open vascular surgery
- PTA:
-
percutaneous transluminal angioplasty
- TASC:
-
Trans-Atlantic Inter-Society Consensus
- VBG:
-
venous bypass graft
References
ACC/AHA 2005 guidelines. (2006). J Am Coll Cardiol. 47: 1239–1312.
Aquarius AE, Denollet J, De Vries J, Hamming JF. (2007). J Vasc Surg. 46: 507–512.
Albers M, Fratezi AC, De Luccia N. (1992). J Vasc Surg. 16: 54–59.
BASIL trial participants. (2005). Lancet. 366: 1925–1934.
Bosch JL, van der Graaf Y, Hunink MGM. (1999). Circulation. 99: 3155–3160.
Breek JC, Hamming JF, De Vries M, van Berge Henegouwen DP, van Heck GL. (1992). J Vasc Surg. 36: 94–99.
Brothers TE, Robinson JG, Elliott BM. (2007). J Vasc Surg. 45: 701–708.
Cherr GS, Wang J, Zimmerman PM, Dosluoglu HH. (2007). J Vasc Surg. 45: 744–750.
Chetter IC, Spark JI, Scott JA, Kent PJ, Berridge DC, Kester RC. (1998). Br J Surg. 85: 951–955.
Chetter IC, Spark JI, Scott JA, Kester RC. (1999). Ann vac Surg. 13: 90–103.
Chong PF, Garratt AM, Golledge J, Greenhalgh RM, Davies AH. (2002). J Vasc Surg. 36: 764–771.
Currie IC, Wilson YG, Bairs RN, Lamont PM. (1995). Eur J Vasc Endovasc Surg. 10: 356–361.
Deneuville M, Perrouillet A. (2006). Ann Vasc Surg. 20: 753–760.
Deneuville M, Pierrot JM, N’Guyen R. (2008). Arch Cardiovasc Dis. 101: 23–29.
Deutschmann HA, Schoellnast H, Temmel W, Deutschmann M, Schwantzer G, Fritz GA, Brodmann M, Hausegger KA. (2007). AJR. 188: 169–175.
De Vries M, Ouwendijk R, Kessels AG, de Haan MW, Flobbe K, Hunink MGM, van Engelshoven JMA, Nelemans JP. (2005). J Vasc Surg. 41: 261–268.
Engelhardt M, Bruijnen H, Scharmer C, Jezdinsky N, Wölfle K. (2006). Eur J Vasc Endovasc Surg. 32: 182–187.
Feinglass J, McCarthy WJ, Slavensky R, Manheim LM, Martin GJ. (2000). J Vasc Surg. 31: 93–103.
Gallagher P, Desmon D. (2007). Prosthet Orthot Int. 31: 167–176.
Goshima KR, Mills JL Sr, Hughes JD. (2004). J Vasc Surg. 39: 330–335.
Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. (1995). N Engl J Med. 332: 556–561.
Gibbons GW, Burgess AM, Guadagnoli E, Pomposelli FB, Freeman DV, Campbell DR, Miller A, Marcaccio EJ, Nordberg P, LoGerfo FW. (1995). J Vasc Surg. 21: 35–45.
Hallin A, Bergqvist D, Fugl-Meyer K, Holmberg L. (1992). Eur J Vasc Endovasc Surg. 24: 255–263.
Hernandez-Osma E, Cairols MA, Marti X, Barjau E, Riera S. (2002). Eur J Vasc Endovasc Surg. 23: 91–94.
Holtzman J, Cadwell M, Walvatne C, Kane R. (1999). J Vasc Surg. 29: 395–402.
Johnson BF, Singh S, Evans L, Drury R, Datta D, Beard JD. (1997). Eur J Vasc Endovasc Surg. 13: 306–314.
Khaira HS, Hanger R, Shearman CP. (1996). Eur J Vasc Endovasc Surg. 11: 65–69.
Kalbaugh CA, Taylor SP, Blackhurst DW, Dellinger MB, Trent EA, Youkey JR. (2006). J Vasc Surg. 44: 296–303.
Klevsgård R, Risberg BO, Thomsen MB, Hallberg IR. (2001). J Vasc Surg. 33: 114–122.
Klevsgård R, Fröberg BL, Risberg BO, Hallberg IR. (2002). J Vasc Surg. 36: 310–317.
Mehta T, Venkata Subramaniam A, Chetter I, McCollum P. (2006). Eur J Vasc Endovasc Surg. 31: 46–52.
Morgan MBF, Crayford T, Murrin B, Fraser CA. (2001). J Vasc Surg. 33: 679–687.
Nehler MR, Coll JR, Hiatt WR, Regensteiner JG, Schnickel GT, Klenke WA, Strecker PK, Anderson MW, Jones DN, Whitchill TA, Moskowitz. (2003). J Vasc Surg. 38: 7–14.
Nguyen LL, Moneta GL, Conte MS, Bandyk DF, Clowes AW, Seely BL, for prevent III investigators. (2006). J Vasc Surg.44: 977–84.
Nicoloff AD, Taylor LM Jr, McLafferty RB, Moneta GL, Porter JM. (1998). J Vasc Surg. 27: 256–263.
Novgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. (2007). J Vasc Surg. 45Suppl: 5A–65A.
Nylaende M, Abdelnoor M, Stranden E, Morken B, Sandbaek G, Risum O, Jorgensen JJ, Lindahl AK, Arnesen H, Seljeflot I, Kroese AJ. (2007). Eur J Vasc Endovasc Surg. 33: 3–12.
Paaske WP, Laustsen J. (1995). Eur J Vasc Endovasc Surg. 10: 226–230.
Peel JP, Donnan PT, Fowkes GR, Ruckley CV. (1993). Eur J Vasc Surg. 7: 448–451.
Pell JP on the behalf of the Scottish Vascular Audit Group. (1995). Eur J Vasc Endovasc Surg. 9: 469–472.
Rajagopalan S, Dellegrottaglie S, Furniss AL, Gillespie BW, Satayathum S, Lameire N, Saito A, Akiba T, Jadoul M, Ginsberg N, Keen M, Port FK, Mukherjee D, Saran R. (DOPPS) (2006). Circulation.114: 1914–1922.
Regensteiner JG, Hargarten ME, Rutherford RB, Hiatt WR. (1993). Angiology. 44: 1–10.
Rucker-Whitaker C, Greenland P, Liu K, Chan C, Guralnik JM, Criqui MH, Taylor L, Pearce WH, McGrae McDermott M. (2004). J Am Geriatr Soc. 52: 922–930.
Sabeti S, Czerwenka-Wenkstetten A, Dick P, Schlager O, Amighi J, Mlekusch I, Mlekusch W, Loewe C, Cejna M, Lammer J, Minar E, Schillinger M. (2007). J Endovasc Ther. 14: 431–437.
Seabrook GR, Cambria RA, Freischlag JA, Towne JB. (1999). Cardiovasc Surg. 7: 279–286.
Tangelder MJ, McDonnel J, Van Busschbach JJ, Buskens E, Algra A, Lawson JA, Eikelboom BC. (1999). J Vasc Surg. 29: 913–919.
Taylor SM, Kalbaugh CA, Blackhurst DW, Hamontree SE, Cull DL, Messich HS, Robertson RT, Lagan EM 3rd, York JW, Carsten CG 3rd, Snyder BA, Jackson MR, Youkey JR. (2005). J Vasc Surg. 42: 227–235.
Taylor SM, Kalbaugh CA, Blackhurst DW, Cass AL, Trent AE, Langan EMIII, Youkey JR. (2006). J Vasc Surg. 44: 747–756.
Thorsen H, McKenna S, Tennant A, Holstein P. (1992). Eur J Vasc Endovasc Surg. 23: 495–499.
Wann-Hansson C, Hallberg IR, Risberg B, Klevsgård R. (2004). Health Qual Life Outcomes. 17: 2–9.
Whyman MR, Fowkes FG, Kerracher EM, Gillespie IN, Lee AJ, Housley E, Ruckley CV. (1996). Eur J Vasc Endovasc Surg. 12: 167–172.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Appendix
Appendix
Key facts of revascularization for lower extremity arterial disease
Level of disease | Type | Material | Mortality % | Indications | Expected 5-year patency % |
---|---|---|---|---|---|
Aorto- iliac | BPGa | Pro | 3.3 | Bilateral, Long aortic lesion | 85–90 |
biAxF | Pro | 7 | 50–76 | ||
ET | Stent | ND | <3 cm stenosis | 77 | |
Iliac arteries | ET | Stent | 1 | Focal stenosis | 64–75 |
Cxo | Pro | 6 | Unilateral occlusion | 55–92 | |
AxF | Pro | 6 | 44–79 | ||
CFA/bifurcation | TEA | Patch | 0–3 | Focal stenosis | 50 |
PFA | TEA | Pro or Ven | |||
SFA/ AK popliteal | BPG | Ven or Pro | 1.3–6 | Multiple lesions | 66/50 |
ET | Stent if failure | 0.9 | Focal lesion | 33–62 | |
BK popliteal | BPG | Ven (GSV) | 1.3–6 | Multiple lesions | 66 |
ET | ND | Focal stenosis | |||
Leg/pedal | BPG | Ven (GSV) | 1.3–7 | Multisegmental CLI only | 74–80 |
ET | Subintimal | ND | 33–51 |
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media LLC
About this entry
Cite this entry
Deneuville, M. (2010). Quality of Life After Revascularization and Major Amputation for Lower Extremity Arterial Disease. In: Preedy, V.R., Watson, R.R. (eds) Handbook of Disease Burdens and Quality of Life Measures. Springer, New York, NY. https://doi.org/10.1007/978-0-387-78665-0_138
Download citation
DOI: https://doi.org/10.1007/978-0-387-78665-0_138
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-78664-3
Online ISBN: 978-0-387-78665-0
eBook Packages: MedicineReference Module Medicine